Stereotactic radiotherapy a viable option in early-stage lung cancer

Share this article:

Although health-related quality of life (HRQOL) frequently deteriorates after surgery for stage I non-small-cell lung cancer (NSCLC), a recent study demonstrated that undergoing treatment with stereotactic ablative radiotherapy (SABR) did not seem to have any negative effects on patients with this disease.

Frank J. Lagerwaard, MD, PhD, and colleagues collected HRQOL data on 382 patients with consecutive stage I NSCLC who were treated with SABR. The patients, who had been referred from 68 centers throughout the Netherlands, had either been deemed unfit for surgery (86%) or had declined surgery (14%). Following SABR, they completed questionnaires, providing information on such factors as their level of physical function, appetite loss, pain, and emotional function. This HRQOL data were available for 282, 212, 144, 56, and 43 patients at 3, 6, 12, 18, and 24 months post-SABR, respectively.

The researchers reported in Journal of Thoracic Oncology (2012;7[7]:1148-1154) that median survival was 40 months, with a 2-year survival rate of 66%. Mean global HRQOL score at baseline was 62.9 ± 1.1; baseline symptom scores were highest for dyspnea (47.1 ± 1.7) and fatigue (37.4 ± 1.3).

Except for a nonsignificant reduction of 2 to 3 points per year in physical functioning scores (mean score at baseline was 61.7 ± 1.1), Lagerwaard's team observed no statistically or clinically significant worsening of any of the HRQOL functioning or symptom scores at any point during follow-up. The authors pointed out that this outcome stands in contrast to that seen among patients with stage 1 NSCLC who undergo surgery instead, as the surgical patients often do experience worse HRQOL posttreatment.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.

Prostate Cancer Prevention Trial identifies men most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.